Executive Summary : | Natural products are the source of inspiration for development of new products for chemistry, pharmacy and medicine. For drug discovery and development, secondary metabolite of natural products is the blessing for human as it is a hidden treasure that need to find out its efficacy to cure diseases. This secondary metabolite synthesizes in define pathway and its production is limited. If efficacy of the molecule is identifying but is challenging to extract in that concentration which can be marketed worldwide. Natural products are the lead compounds for many drug discovery and development program, example is aspirin. The natural products are the most important source for modern medicine for development of drug in the areas of anti-inflammatory, antiviral and chemotherapy etc. All the natural products are not transform as a drug as its pure form due to its bioavability. Therefore, to enhance the bioavaibility, there is a need to synthesize its derivative which not only enhance the bioavaibility but also improves its efficacy as druggable molecule. To enhance therapeutic index and reduce toxicity issues of cytotoxic of chemotherapy drug, natural product derived small molecules provides the opportunity to develop a drug for treatment of diseases. Fistein is bioactive flavonol molecule from the flavonoid group of polyphenols found in fruits and vegetables such as strawberry, grape, apple etc. which has anti-proliferative properties that is one of the required characteristic of cancer drug as cancer cells possess uncontrolled cell proliferation. It was observed that fistein works as inhibitor of MAPK, Aurora kinase, PI3K, ERK AMPK, NF-κB, Topoisomerase II as well as downregulate MMP and enhance autophagy in cancerous cells. Hence, fistein analogs which can work as prodrug as well as enhance the bioavaibility is offer prospect to develop a promising selective target inhibitor drug. On the basis of literature survey and preliminary work done with fistein (pure compound), we hypothesized that fistein or its analogs has inhibitory activity on tyrosine kinase (Trk). Inhibition (dephosphorylation) of Trk, surfactosome, down the line dephosphorylate other kinases like MAPK, PI3K, ERK. On dephosphorylation, the survival pathway of cancer will be altered into death pathway. |